XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) has announced that its director and founder Professor Dr Raimar Loebenberg is the 2022 recipient of the Canadian Society for Pharmaceutical Sciences (CSPS) Award of Leadership in Canadian Pharmaceutical Sciences.
The award is bestowed upon an individual who has demonstrated leadership in advancing the cause of pharmaceutical research and development in Canada.
In addition to his role at XPhyto, Dr Loebenberg is a Professor in the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (UoA) and the founder and director of the Drug Development and Innovation Centre (DDIC), UoA.
XPhyto said it is “proud” to have Dr Loebenberg on its board of directors and leading its psychedelic medicine program with a multi-pronged approach, including GMP drug synthesis, proprietary drug delivery systems, novel psychedelic analogue engineering, and clinical validation.
READ: XPhyto Therapeutics says pharmaceutical manufacturing expert Dr Florian A. Sahr has joined its European operations as project management head
Dr Loebenberg received a Bachelor of Science degree in Pharmacy from the Johannes Gutenberg-University, Mainz, Germany and a PhD in Pharmaceutics from the Johann Wolfgang Goethe-University, Frankfurt, Germany.
His research interests are in biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis and leishmanasis. He is a co-founder of RS Therapeutics Inc, a foam-based topical drug delivery company.
Dr Loebenberg's recent notable positions include as president of the Canadian Society for Pharmaceutical Sciences 2014 to 2015, vice chair of the United States Pharmacopeia Dietary Supplement Expert Committee 2016 to 2017, current member of the United States Pharmacopeia Dietary Supplement Expert Committee, current vice chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science, and current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.
XPhyto is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions.
The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
Contact the author at jon.hopkins@proactiveinvestors.com